EUVIMEDSkopri EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY 4.0

Effect of the Multi‐Strain Probiotic SYN ‐53 in the Management of Allergic Rhinoconjunctivitis

Karl-Christian Bergmann, Torsten Zuberbier iD

Allergy · 2025

DOI: 10.1111/all.16634 ↗

At a glance

Randomisierte kontrollierte Studie in Allergy, 2025. Written by Karl-Christian Bergmann and 1 co-authors. Institution: Institute of Allergology, Charité Universitätsmedizin, Berlin, Germany. Major MEDLINE topics: Probiotics, Conjunctivitis, Allergic, Rhinitis, Allergic, Rhinitis, Allergic, Seasonal. Cited 4 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY 4.0). Funded by: Synformulas.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Dysbiosis is increasingly linked to allergy development. This study evaluates the efficacy of the multi‐strain probiotic SYN‐53 in the management of allergic rhinoconjunctivitis (ARC). Eighty‐four subjects with confirmed grass pollen allergy underwent up to three bi‐weekly 3‐day intake cycles with SYN‐53 or placebo. After each cycle, subjects were exposed to grass pollen in an allergen exposure chamber. ARC symptoms were assessed using the Total Symptom Score (TSS) before and after each use of SYN‐53. After one intake cycle, SYN‐53 already showed a trend towards greater efficacy over placebo, which became significant after two cycles (ΔTSS MAX : −3.44 ± 0.42 vs. −1.87 ± 0.37; p = 0.0067), with 38% vs. 24% symptom relief. In subjects with moderate to severe symptoms, SYN‐53 was already significantly superior after one single intake cycle and improved further after two cycles (ΔTSS MAX : −4.78 ± 0.51 vs. −2.43 ± 0.47; p = 0.0014), with 45% vs. 26% symptom relief. SYN‐53 is effective in the management of ARC, highlighting the role of bacterial diversity and dosage in probiotic nutritional supplements.

Subjects

MeSH terms (MEDLINE)

ProbioticsConjunctivitis, AllergicRhinitis, AllergicRhinitis, Allergic, SeasonalHumansAdultFemaleMaleTreatment OutcomeYoung AdultMiddle AgedPollenAllergensDisease Management

Author keywords

allergen exposure chamberallergic rhinitisallergic rhinoconjunctivitismicrobiomeprobiotic

Substances

Allergens

Authors and institutions

  • Institute of Allergology, Charité Universitätsmedizin, Berlin, Germany.
  • Corporate Member of Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin, Germany.
  • Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.

ORCID profiles: Torsten Zuberbier

Funding

  • Synformulas

Cite

APA

Bergmann, K. C., & Zuberbier, T. (2025). Effect of the Multi‐Strain Probiotic SYN ‐53 in the Management of Allergic Rhinoconjunctivitis. Allergy. https://doi.org/10.1111/all.16634

Vancouver

Bergmann KC, Zuberbier T. Effect of the Multi‐Strain Probiotic SYN ‐53 in the Management of Allergic Rhinoconjunctivitis. Allergy. 2025. doi:10.1111/all.16634

BibTeX
@article{Bergmann2025,
  author = {Bergmann, Karl-Christian and Zuberbier, Torsten},
  title = {Effect of the Multi‐Strain Probiotic SYN ‐53 in the Management of Allergic Rhinoconjunctivitis},
  journal = {Allergy},
  year = {2025},
  doi = {10.1111/all.16634}
}
Start for free →